Issues related to UNOS and heart transplant criteria.
H.R.4128: VALID Act of 2021.
H.R.7213 - Equitable Community Access to Pharmacist Services Act.
SUPPORT Act reauthorization.
Duration: July 1, 2010
to
present
General Issues: Health Issues , Taxation/Internal Revenue Code , Copyright/Patent/Trademark , Medicare/Medicaid , Defense , Trade (Domestic & Foreign) , Veterans , Budget/Appropriations , Natural Resources , Agriculture , Food Industry (Safety, Labeling, etc.)
Spending: about $2,750,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: House of Representatives, U.S. Senate, Health & Human Services - Dept of (HHS), Office of the Vice President of the United States, Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), U.S. Senate,, House of Representatives,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox
Asst for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Cong. Porter Goss
House Rules Comm Assoc, Subcomm Staff Dir.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 22.
Original Filing: 301575582.xml
Lobbying Issues
Issues related to UNOS and heart transplant criteria.
H.R.4128: VALID Act of 2021.
H.R.7213 - Equitable Community Access to Pharmacist Services Act.
SUPPORT Act reauthorization.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 18.
Original Filing: 301529192.xml
Lobbying Issues
Issues related to UNOS and heart transplant criteria.
H.R.4128: VALID Act of 2021.
H.R.7213 - Equitable Community Access to Pharmacist Services Act.
Reauthorization of PAHPA.
SUPPORT Act reauthorization.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511868.xml
Lobbying Issues
Issues related to UNOS and heart transplant criteria.
H.R.4128 - VALID Act of 2021.
H.R.7213 - Equitable Community Access to Pharmacist Services Act.
Reauthorization of PAHPA.
SUPPORT Act reauthorization.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301489614.xml
Lobbying Issues
Issues related to UNOS and heart transplant criteria.
H.R.2369 - VALID Act of 2023.
H.R.7213 - Equitable Community Access to Pharmacist Services Act.
Reauthorization of PAHPA.
SUPPORT Act reauthorization.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301467234.xml
Lobbying Issues
Issues related to UNOS and heart transplant criteria.
H.R.2369 - VALID Act of 2023.
H.R.7213 - Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435742.xml
Lobbying Issues
H.R.4128: VALID Act of 2021.
H.R.4373 - Further Additional Continuing Appropriations and Extensions Act, 2023, as it relates to FDA policy riders.
Education around CDC pain management guidelines.
H.R.7213 - Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413184.xml
Lobbying Issues
H.R.5376, "Build Back Better Act", as it relates to international tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.4128: VALID Act of 2021.
21st Century Cures 2.0.
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Legislation related to data privacy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2022
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 19, 2022.
Original Filing: 301386130.xml
Lobbying Issues
H.R.5376, "Build Back Better Act", as it relates to international tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.4128: VALID Act of 2021.
21st Century Cures 2.0.
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2022
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 19, 2022.
Original Filing: 301363350.xml
Lobbying Issues
H.R.5376, "Build Back Better Act", as it relates to international tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.4128: VALID Act of 2021.
21st century cures 2.0.
Reauthorization of the Medical Device User Fee Act and related issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2021
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331657.xml
Lobbying Issues
CMS Medicare Coverage of CGM (Continuous Glucose Monitoring) devices.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.5376, "Build Back Better Act", as it relates to international tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.4128: VALID Act of 2021.
21st century cures 2.0.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2021
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313348.xml
Lobbying Issues
CMS Medicare Coverage of Breakthrough Medical Devices.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 22 Budget Reconciliation as it relates to international tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.4128: VALID Act of 2021.
21st century cures 2.0.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 19, 2021.
Original Filing: 301283303.xml
Lobbying Issues
H.R. 4128: VALID Act of 2021.
Education related to COVID-19 testing and implementation of FY 2021 Consolidated Appropriations Act.
21st Century Cures 2.0.
Issues related to adult malnutrition.
Legislation related to medical device shortages.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
CY 2021 DMEPOS rule as it relates to continuous glucose monitors.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301258209.xml
Lobbying Issues
H.R.6102: VALID Act of 2020.
Education related to COVID-19 testing.
Education related to Telehealth during COVID-19.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS National Coverage Decision for Transcatheter Edge to Edge Repair.
CY 2021 DMEPOS rule as it relates to continuous glucose monitors.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240670.xml
Lobbying Issues
H.R.6102: VALID Act of 2020.
Education related to COVID-19 testing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS National Coverage Decision for Transcatheter Edge to Edge Repair.
CMS Quality Measure Related to Older Adult Malnutrition.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R.133: Consolidated Appropriations Act, 2021 as it relates to tax extender.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222613.xml
Lobbying Issues
H.R.6102: VALID Act of 2020.
H.R.5663: Safeguarding Therapeutics Act.
Education related to COVID-19 testing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS National Coverage Decision for Transcatheter Edge to Edge Repair.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301201578.xml
Lobbying Issues
H.R.6102: VALID Act of 2020.
Legislation around 21st Century Cures 2.o.
Education about COVID-19 testing.
H.R. 7026: Rapid Testing for Communities Act of 2020.
H.R.7025: Diagnostic Testing for Public Health Labs Act of 2020.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301176650.xml
Lobbying Issues
H.R.6102: VALID Act of 2020.
H.R.2064: Sunshine for Samples Act.
H.R.2791: Infant Formula Protection Act of 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS National Coverage Decision on coverage for transcather mitral valve repair.
HHS Transparency in Coverage proposed rule.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
4th Quarter, 2019
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128849.xml
Lobbying Issues
Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act.
H.R.2064: Sunshine for Samples Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1864, FY 2020 Appropriations as it relates to H.R.2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Administration Executive Order entitled Protecting and Improving Medicare for Our Nations Seniors.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS)
3rd Quarter, 2019
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078358.xml
Lobbying Issues
Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act.
H.R.2113: Prescription Drug STAR Act.
H.R.2064: Sunshine for Samples Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2020 NDAA - education about CGM coverage in TRICARE.
2nd Quarter, 2019
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301056749.xml
Lobbying Issues
Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act.
Education about adult malnutrition
H.R.2113: Prescription Drug STAR Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Education about the implementation of PAMA with respect to physician office labs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2020 NDAA - education about CGM coverage in TRICARE.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301035080.xml
Lobbying Issues
Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Education about the implementation of PAMA with respect to physician office labs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2020 NDAA - education about CGM coverage in TRICARE.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015856.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4617: Protect Medical Innovation Act and H.R.88 as it relates to the medical device tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Education about the implementation of PAMA with respect to physician office labs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about medical device coverage and reimbursement issues in Japan.
Agencies Lobbied
Office of the Vice President of the United States
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 16, 2018.
Original Filing: 300985880.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
H.R.6378/S.2852: Reauthorization of PAHPA (Pandemic All-Hazards Preparedness Act).
H.R.6: Support for Patients and Communities Act as it relates to provisions designed to promote the importance of non-pharmacological pain treatment options, including medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4617: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Education about the importance of proper reimbursement for home monitoring services for anticoagulation management.
Education about the regulation of continuous glucose monitor technologies including CMS regulation of CGM.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education around VA coverage of CGM devices.
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300975545.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
Reauthorization of PAHPA (Pandemic All Hazards Preparedness Act).
H.R.6: Support for Patients and Communities Act as it relates to provisions designed to promote the importance of non-pharmacological pain treatment options, including medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4617: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Education about the importance of proper reimbursement for home monitoring services for anticoagulation management.
Education about the regulation of continuous glucose monitor technologies including CMS regulation of CGM.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300950234.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
Education about the importance of non-pharmacological pain treatment options, including medical devices.
H.R.195, as it relates to the HEALTHY KIDS Act CHIP reauthorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2018 Continuing resolution as it relates to suspension of the medical device tax.
H.R.4617: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare conditions of participation as it relates to antibiotics.
Education about the regulation of continuous glucose monitor technologies.
Agencies Lobbied
U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018.
H.R.1625: Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929292.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1/S.1: Tax Cuts and Jobs Act.
H.R.4617: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Executive Office of the President (EOP)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare quality measures related to malnutrition among older Americans.
H.R.849: Protecting Seniors Access to Medicare Act.
H.R.3271: Protecting Access to Diabetes Supplies Act of 2017.
Implementation of PAMA (Protecting Access to Medicare Act of 2014).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915499.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
H.R. 1628: American Health Care Act of 2017.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare quality measures related to malnutrition among older Americans.
H.R. 3271: Protecting Access to Diabetes Supplies Act of 2017.
Implementation of PAMA (Protecting Access to Medicare Act of 2014).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300897216.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
Issues related to WHO and diagnostic tests.
H.R. 1628: American Health Care Act of 2017.
H.R.2430: FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare quality measures related to malnutrition among older Americans.
Implementation of PAMA (Protecting Access to Medicare Act of 2014).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 21, 2017.
Original Filing: 300878586.xml
Lobbying Issues
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act.
Issues related to Nutrition Facts Panel harmonization.
Medical Device User Fee Act Reauthorization.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare quality measures related to malnutrition among older Americans.
Implementation of PAMA (Protecting Access to Medicare Act of 2014).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848330.xml
Lobbying Issues
H.R. 34: 21st Century Cures Act conference report, including issues related to site neutral payment policy.
FY 2017 House and Senate Agriculture Appropriations bills as it relates to regulation of laboratory developed tests and the development of legislation related to regulation of LDT's.
Issues related to malnutrition among older Americans.
Education about the grey market sale of diabetes test strips.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834850.xml
Lobbying Issues
H.R. 1559/S. 764: Safe and Accurate Food Labeling Act of 2014.
H.R. 6: 21st Century Cures Act.
WHO Guidance on Promotion of Food for Infants and Children.
FY 2017 House and Senate Agriculture Appropriations bills as it relates to regulation of laboratory developed tests and the development of legislation related to regulation of LDT's.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300815072.xml
Lobbying Issues
H.R. 1559/S. 764: Safe and Accurate Food Labeling Act of 2014.
H.R. 6: 21st Century Cures Act.
WHO Guidance on Promotion of Food for Infants and Children.
FY 2017 House and Senate Agriculture Appropriations bills as it relates to regulation of laboratory developed tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.5273: Helping Hospitals Improve Patient Care Act of 2016.
H.R.5210: PADME Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300803016.xml
Lobbying Issues
H.R. 1559: Safe and Accurate Food Labeling Act of 2014.
H.R. 6: 21st Century Cures Act.
WHO Guidance on Promotion of Food for Infants and Children.
Draft legislation dealing with regulation of laboratory developed tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.3291: Medicare Crosswalk Hospital Code Development Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Child Nutrition Reauthorization.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776285.xml
Lobbying Issues
H.R. 1559: Safe and Accurate Food Labeling Act of 2014.
H.R. 6: 21st Century Cures Act, specifically as it relates to DMEPOS Competitive Bidding and Medicaid.
Draft legislation dealing with regulation of laboratory developed tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.3291: Medicare Crosswalk Hospital Code Development Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
P.L. 114-113: "Consolidated Appropriations Act" with respect to the Protecting Americans from Tax Hikes Act and provisions related to delay in the medical device tax and excise tax on high value health plans;James Zadroga 9/11 Health and Compensation Reauthorization as it relates to offsets impacting DMEPOS in Medicaid.
S. 2045: Middle Class Health Benefits Tax Repeal Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored Child Nutrition Reauthorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 114-74: Bipartisan Budget Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763496.xml
Lobbying Issues
H.R. 1559: Safe and Accurate Food Labeling Act of 2014.
Education on malnutrition awareness and the importance of screening.
H.R. 6: 21st Century Cures Act, specifically as it relates to DMEPOS Competitive Bidding and Medicaid.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.3291: Medicare Crosswalk Hospital Code Development Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
H.R. 1430: Permanent CFC Look-Through Act of 2015.
S. 2045: Middle Class Health Benefits Tax Repeal Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Educated staff about the WIC program.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2015
W Strategies, LLC amended a lobbying report for representation of Abbott Laboratories in Q32015 on Oct. 20, 2015.
Original Filing: 300763555.xml
Lobbying Issues
H.R. 1559: Safe and Accurate Food Labeling Act of 2014.
Education on malnutrition awareness and the importance of screening.
H.R. 6: 21st Century Cures Act, specifically as it relates to DMEPOS Competitive Bidding and Medicaid.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.3291: Medicare Crosswalk Hospital Code Development Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
H.R. 1430: Permanent CFC Look-Through Act of 2015.
S. 2045: Middle Class Health Benefits Tax Repeal Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Educated staff about the WIC program.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300743418.xml
Lobbying Issues
H.R. 1559: Safe and Accurate Food Labeling Act of 2014.
Educated staff about FDA guidances, specifically with respect to glucose meters and certain medical foods.
H.R. 6: 21st Century Cures Act, specifically as it relates to DMEPOS Competitive Bidding and Medicaid.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
New Technology Add-On Payment in the Medicare IPPS.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Educated staff about the WIC program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1314: Trade Preferences Extension Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 17, 2015.
Original Filing: 300718799.xml
Lobbying Issues
H.R. 1559: Safe and Accurate Food Labeling Act of 2014.
Educated staff about FDA guidances, specifically with respect to glucose meters and certain medical foods.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21 Century Cures).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
New Technology Add on Payment in the Medicare IPPS.
Medicare reimbursement of certain lab developed tests in cancer care.
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Educated staff about the WIC program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704085.xml
Lobbying Issues
H.R. 4432: Safe and Accurate Food Labeling Act of 2014.
Educated staff about FDA guidances, specifically with respect to glucose meters and certain medical foods.
Educated staff about FDA interim final rule dealing with infant formulas.
FDA draft guidance related to regulatory oversight of lab developed tests.Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 5780: Protecting the Integrity of Medicare Act of 2014.
H.R. 4920: Medicare DMEPOS Competitive Bidding Improvement Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
H.R. 5771: Tax Increase Prevention Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Educated staff about the WIC program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3547: Consolidated Appropriations Act for FY 2015.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300684665.xml
Lobbying Issues
H.R. 4432: Safe and Accurate Food Labeling Act of 2014.
Educated staff about FDA guidances, specifically with respect to glucose meters and certain medical foods.
Educated staff about FDA interim final rule dealing with infant formulas.
FDA draft guidance related to regulatory oversight of lab developed tests.Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Payments issues related to transcatheter mitral valve repair procedures in the Medicare IPPS Final Rule for FY 2015.
H.R. 2925: Strengthening Medicare Anti-Fraud Measures Act of 2013.
Education about federal regulations related to "anti-switching" rules which prohibit contract suppliers from incentivizing Medicare beneficiaries to switch their current blood glucose monitor.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
H.R.4438: American Research and Competitiveness Act of 2014.
S.2360/H.R. 4679: Stop Corporate Inversions Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 14, 2014.
Original Filing: 300656423.xml
Lobbying Issues
H.R. 4432: Safe and Accurate Food Labeling Act of 2014.
Educated staff about FDA guidances, specifically with respect to glucose meters and certain medical foods.
Educated staff about FDA interim final rule dealing with infant formula.Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education with respect to implementation issues in the Medicare Competitive Bidding program, specifically as it relates to access to brand name diabetes test strips.
Payments issues related to transcatheter mitral valve repair procedures in the Medicare IPPS Final Rule for FY 2015.
H.R. 2925: Strengthening Medicare Anti-Fraud Measures Act of 2013.Education about federal regulations related to "anti-switching" rules which prohibit contract suppliers from incentivizing Medicare beneficiaries to switch their current blood glucose monitor.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
H.R.4438: American Research and Competitiveness Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
International trade issues related to nutrition.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 14, 2014.
Original Filing: 300635663.xml
Lobbying Issues
Educated staff about legislative initiatives to encourage labeling of genetically modified foods.
Educated staff about FDA guidances, specifically with respect to glucose meters and certain medical foods.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013.
Education with respect to implementation issues in the Medicare Competitive Bidding program, specifically as it relates to access to brand name diabetes test strips.
H.R. 4302: Protecting Access to Medicare Act of 2014, specifically as it relates to clinical lab fee schedule reforms.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 14, 2014.
Original Filing: 300621907.xml
Lobbying Issues
Education on the importance of proper infant nutrition, including the role of infant formula in the WIC program.
Monitored legislative initiatives to encourage labeling of genetically modified foods.
Educated staff about FDA regulation and certain medical foods.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013.
Education with respect to implementation issues in the Medicare Competitive Bidding program, specifically as it relates to access to brand name diabetes test strips.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1947: Federal Agriculture Reform and Risk Management Act of 2013 with respect to Goodlatte-Scott amendment to reform the dairy program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 16, 2013.
Original Filing: 300601796.xml
Lobbying Issues
Education on the importance of proper infant nutrition, including the role of infant formula in the WIC program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013.
Education with respect to implementation issues in the Medicare Competitive Bidding program, specifically as it relates to access to brand name diabetes test strips.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1947: Federal Agriculture Reform and Risk Management Act of 2013 with respect to Goodlatte-Scott amendment to reform the dairy program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 19, 2013.
Original Filing: 300577231.xml
Lobbying Issues
Education on the importance of proper infant nutrition, including the role of infant formula in the WIC program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1947: Federal Agriculture Reform and Risk Management Act of 2013 with respect to Goodlatte-Scott amendment to reform the dairy program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 16, 2013.
Original Filing: 300553168.xml
Lobbying Issues
Education on the importance of proper infant nutrition, including the role of infant formula in the WIC program.
Reauthorization of the Animal Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to Medicare reimbursement for diabetic supplies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY '13 Senate Continuing Resolution Appropriations - Moran amendment to enhance funding for the FAA control tower program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 14, 2013.
Original Filing: 300536603.xml
Lobbying Issues
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 6446: To create incentive for innovative diagnostics by improving the process for determining Medicare payment rates for new tests.
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 16, 2012.
Original Filing: 300512439.xml
Lobbying Issues
P.L. 112-144, The Food and Drug Administration Safety and Innovation Act of 2012.
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 6446: To create incentive for innovative diagnostics by improving the process for determining Medicare payment rates for new tests.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.J.Res. 117: Continuing Appropriations Resolution for Fiscal Year 2013.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 19, 2012.
Original Filing: 300493994.xml
Lobbying Issues
H.R. 5651: Food and Drug Administration Reform Act of 2012, S. 3187: Food and Drug Administration Safety and Innovation Act of 2012, as it relates to provisions affecting drug and medical device approval process.
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 18, 2012.
Original Filing: 300463989.xml
Lobbying Issues
H.R. 452: Medicare Decisions Accountability Act.
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
H.R. 3497: Moddern Cures Act as it relates to reimbursement of diagnostics.H.R. 5: Help Efficient, Accessible, Low-cost Timely Healthcare Act.
H.R. 452: Medicare Decisions Accountability Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Development of reauthorizing legislation implementing the Prescription Drug User Fee Act (PDUFA) and Medical Device User Fee Act agreements and related issues.
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 436: Protect Medical Innovation Act.
Monitoring H.R. 3630: Middle Class Tax Relief and Job Creation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H. Con. Res. 112: FY 2013 Budget Resolution.
Education regarding the importance of maintaining current law as it relates to biosimilars and opposing efforts in the President's Budget to shorten the term of data exclusivity for innovator biologics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445486.xml
Lobbying Issues
H.R. 452 - Medicare Decisions Accountability Act of 2011.
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
H.R. 3497: Moddern Cures Act of 2011 as it relates to reimbursement of diagnostics.P.L. 112-25: The Budget Control Act of 2011 as it relates to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2011
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300423911.xml
Lobbying Issues
Outreach and education to repeal the Independent Payment Advisory Board.
H.R. 452 - Medicare Decisions Accountability Act of 2011.
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals to impose mandatory rebates in the Part D Program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Educated staff about maintaining strong Intellectual Property provisions in the TransPacific Partnership Agreement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2011
In Q2, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on July 19, 2011.
Original Filing: 300395798.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
H.R. 5 - The Health Act.
Educated staff about issues concerning the 510(k) device approval process.S. 17 - Medical Device Access and Innovation Act.
H.R. 436 - Protect Medical Device Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Medicare and Medicaid FAST Act.
Outreach and education to repeal the Independent Payment Advisory Board.
H.R. 452 - Medicare Decisions Accountability Act of 2011.
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to opposeefforts to impose mandatory government rebates in that program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent Reform
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Educated staff about maintaining strong Intellectual Property provisions in the TransPacific Partnership Agreement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2011
In Q1, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on April 16, 2011.
Original Filing: 300369081.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Judiciary issues related to H.R. 5 - The Health Act.
H.R. 1065 - Pill Mill Crackdown Act of 2011.Educated staff about issues concerning the 510(k) device approval process.
S. 17 - Medical Device Access and Innovation Act
H.R. 436 - Protect Medical Device Innovation Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 675 - "To expand the permissive exclusion from participation in federal health care programs to individuals and entities affiliated with sanctioned entities."
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent Reform
S.23 - America Invents Act of 2011
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Jan. 12, 2011.
Original Filing: 300346571.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Child Nutrition
H.R. 5504 - Improving Nutrition for America's Children Act
S. 3307 - Healthy, Hunger-Free Kids Act of 2010
S. 510 - FDA Food Safety Modernization Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Food Industry (Safety, Labeling, etc.)
3rd Quarter, 2010
In Q3, W Strategies, LLC lobbied for Abbott Laboratories , earning $50,000. The report was filed on Oct. 18, 2010.
Original Filing: 300321236.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Child Nutrition
H.R. 5504 - Improving Nutrition for America's Children Act
S. 3307 - Healthy, Hunger-Free Kids Act of 2010
S. 510 - FDA Food Safety Modernization Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Food Industry (Safety, Labeling, etc.)
3rd Quarter, 2010
W Strategies, LLC filed a lobbying registration on Aug. 9, 2010 to represent Abbott Laboratories, effective July 1, 2010.
Original Filing: 300306736.xml
Issue(s) they said they’d lobby about: Implementation of PPACA, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Patent Reform.
American Jobs and Closing Tax Loopholes. Child nutrition. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate